This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail email@example.com.